In clinical trials for nasal spray treatment
Advantages of easy storage and distribution and convenient use
Expected to be more popular in the future
[아시아경제 김나연 인턴기자] It has been confirmed that the new COVID-19 nasal spray treatment has superior performance than the antibody treatment currently in use. It showed a high therapeutic effect regardless of the type of mutated virus.
As phase 1 clinical trials for humans are underway, interest is gathering whether a new therapeutic agent that suppresses the Corona 19 virus will emerge just by spraying a spray into the nose.
Researchers at Northwestern University, University of Washington, and University of Washington Medical School announced that they have developed a new protein-based antiviral nasal spray treatment and have started Phase 1 clinical trials in humans.
The research team designed a protein that inhibits the ability of the COVID-19 virus to penetrate human cells with a computer, purified it in a laboratory, and made it into a spray.
In preclinical studies on animals, it was found that the virus neutralizing ability was similar to or greater than that of the antibody treatment currently in use with US Food and Drug Administration (FDA) approval. In particular, it worked for all mutations, including delta and omicron. The results of this study were published in the international scientific journal ‘Science Translational Medicine’ on the 12th (local time).
Previously, the research team used a supercomputer to design a protein that can stick to the vulnerable part of the surface of the spike protein used when the Corona 19 virus penetrates the human body, and published a paper in the international academic journal ‘Science’ in 2020.
The antiviral protein blocks the binding of the spike protein to the ACE2 receptor for penetration into the body while maintaining the binding to the spike protein of the Corona 19 virus. In particular, the mini-binder developed by the research team maintained its effectiveness even in the case of COVID-19 micron mutation.
The research team said, “The protein that is the basis of the developed antiviral spray treatment can be produced on a large scale by microorganisms, so it is cost-effective and efficient to manufacture.” there,” he said. He also hoped that “if the clinical trial is successfully completed, it can be conveniently obtained from pharmacies and may play a role in preventing infection with the COVID-19 virus.”
Meanwhile, in Korea, interest in spray-type medicines that are sprayed into the nose has recently been attracting attention.
In particular, it is reported that the sales of cold masks increased by 1000% compared to the first quarter of this year and the previous quarter because they are effective in preventing the penetration of respiratory viruses as a drug that forms a protective film inside the nose.
However, the cold mask was not originally created for the purpose of treating COVID-19, and there is a limitation in that the study was only proven through in vitro cell experiments.
SK Bioscience has also recently started developing a nasal COVID-19 drug with the International Aids Vaccine Promotion Agency (IAVI) and the University of Washington Antigen Design Research Institute (IPD).
Intern reporter Kim Na-yeon [email protected]
Source: 아시아경제신문 실시간 속보 by www.asiae.co.kr.
*The article has been translated based on the content of 아시아경제신문 실시간 속보 by www.asiae.co.kr. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!